https://www.statnews.com/2017/06/16/white-house-drug-prices/
President Trump is expected to issue an executive order on drug pricing soon. A Kaiser Health News investigation reveals pharma's effort to influence that order.
According to the documents — the latest of which is dated June 1— the working group focused on the following ”principles" and ”talking points":
1. Extending the patent life of drugs in foreign markets to ”provide for protection and enforcement of intellectual property rights." This will ensure ”that American consumers do not unfairly subsidize research and development for people throughout the globe."
Extending monopoly protections for drugs overseas has been one of the pharmaceutical industry's top priorities since the Trans-Pacific Partnership was defeated last year.
That policy would push up global drug prices, according to Médecins Sans Frontières.
2. Promoting competition in the U.S. drug market — both by ”modernizing our regulatory and reimbursement systems" and limiting ”barrier to entry, including the cost of research and development," according to the documents.
The working group also discussed two broad policy ideas that have been championed by the pharmaceutical industry, according to sources familiar with the process:
3. Value-based pricing, when pharmaceutical companies keep the list prices of drugs unchanged but offer rebates if patients don't improve. It's unclear who would audit the effectiveness of the drugs, what criteria they would use to evaluate them and who would receive the rebates. Grogan invited Robert Shapiro — an adviser for Gilead and former secretary of Commerce under President Bill Clinton — to brief the working group on value-based pricing on May 18. Shapiro is the chairman and co-founder of Sonecon LLC, a Washington, D.C., firm that consulted with Gilead, Amgen and PhRMA, according to his curriculum vitae.
4. Grogan and Shapiro also discussed issuing 10-year U.S. Treasury bonds to drug manufacturers to pay for expensive, hepatitis C drugs like Sovaldi and Harvoni under Medicare and Medicaid, to avoid rationing drugs to the sickest patients. The 2015 Senate investigation, for example, found that though Medicaid spent more than $1 billion on Sovaldi, just 2.4 percent of Medicaid patients with hepatitis C were treated.
After the working group's first meeting on May 4, Grogan distributed detailed policy recommendations on expediting generic drug approvals, creating a new tax credit ”of up to 50 percent" for investments in generic drug manufacturing, distribution and research and development. The documents also propose scaling back the 340B program, which requires drug manufacturers to provide some medicines at a discount to hospitals that treat low-income patients.
Most of these policies would not ease patient costs, and at least one would increase prices, say experts who reviewed the documents at the request of Kaiser Health News.